AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7862217 — intervention group
Group type: EXPERIMENTAL
Intervention: First blood pressure measurement low (diastolic pressure 95-105 mmHg)
Number of subjects: 94
Study 7862217 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory blood pressure measurement (ABM)
Number of subjects: 94
Study 1786763 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation with twice-a-day irradiation (Group B)
Number of subjects: 80
Study 1786763 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation with three-times-a-day irradiation (Group C)
Number of subjects: 80
Study 1786763 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fractionation (Group A)
Number of subjects: 80
Study 7050702 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 450
Study 7050702 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 450
Study 7050702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 31581816 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based pre-screening
Number of subjects: 19022
Study 31581816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-step, semi-automated screening process
Number of subjects: 19022
Study 31581816 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralisation and automation of screening activities
Number of subjects: 19022
Study 29713841 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peel 70%
Number of subjects: 20
Study 29713841 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser resurfacing
Number of subjects: 20
Study 26725988 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mask Ventilation (FMV)
Number of subjects: 41
Study 26725988 — intervention group
Group type: COMPARATOR
Intervention: Nasal Mask Ventilation (NMV)
Number of subjects: 41
Study 26725988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Mask Ventilation (NMV) with MCM
Number of subjects: 41
Study 25378507 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-trained group
Number of subjects: 48
Study 25378507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 22488038 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chronomodulated delivery of 5-fluorouracil, leucovorin and oxaliplatin
Number of subjects: 77
Study 22488038 — intervention group
Group type: COMPARATOR
Intervention: Conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin
Number of subjects: 77
Study 21416914 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-free surgical scrub procedure (group B)
Number of subjects: 400
Study 21416914 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical scrub technique (group A)
Number of subjects: 400
Study 21416914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 17390930 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention
Number of subjects: 0
Study 17390930 — intervention group
Group type: COMPARATOR
Intervention: Spouses
Number of subjects: 0
Study 17390930 — intervention group
Group type: COMPARATOR
Intervention: Patients
Number of subjects: 0
Study 15592062 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tamsulosin once daily every day
Number of subjects: 140
Study 15592062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin once daily every other day
Number of subjects: 140
Study 15592062 — intervention group
Group type: COMPARATOR
Intervention: discontinued tamsulosin
Number of subjects: 140
Study 12095019 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg kg(‐1) plus fentanyl 1 microg kg(‐1))
Number of subjects: 60
Study 12095019 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (8% plus fentanyl 1 microg kg(‐1))
Number of subjects: 60
Study 12095019 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 12095019 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 10203562 — intervention group
Group type: EXPERIMENTAL
Intervention: High selenium diet (226.5 microg/d)
Number of subjects: 27
Study 10203562 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate
Number of subjects: 27
Study 10203562 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli
Number of subjects: 27
Study 10203562 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenite
Number of subjects: 27
Study 10203562 — intervention group
Group type: EXPERIMENTAL
Intervention: High selenium diet
Number of subjects: 27
Study 7600031 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (50 mg/m2/day) p.o. for 21 consecutive days and cisplatin (100 mg/m2) i.v. on day 1 every 28 days for up to six courses
Number of subjects: 60
Study 7600031 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin combination therapy
Number of subjects: 60
Study 2167360 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous hydroxyapatite (PHA)
Number of subjects: 12
Study 2167360 — intervention group
Group type: COMPARATOR
Intervention: Decalcified freeze‐dried bone allograft (DFDB)
Number of subjects: 12
Study 220889 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of naloxone
Number of subjects: 7
Study 220889 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorphin injections
Number of subjects: 7
Study 220889 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous beta-endorphin
Number of subjects: 7
Study 31614373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff vision device (EVD)
Number of subjects: 250
Study 31614373 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy without cap
Number of subjects: 250
Study 30821652 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cold air at 0, -10, and -17°C during rest and moderate-intensity exercise
Number of subjects: 34
Study 28435487 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 90
Study 28435487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25599230 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) ON
Number of subjects: 18
Study 25599230 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord stimulation (SCS) OFF
Number of subjects: 18
Study 24341049 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 100
Study 24341049 — intervention group
Group type: COMPARATOR
Intervention: Control group (non GIK)
Number of subjects: 100
Study 20495801 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-free computer-navigation system (navigated group)
Number of subjects: 64
Study 20495801 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique (freehand group)
Number of subjects: 64
Study 19808716 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 217
Study 19808716 — intervention group
Group type: COMPARATOR
Intervention: Aortoiliac revascularization with stent
Number of subjects: 217
Study 19808716 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical care
Number of subjects: 217
Study 16704584 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium permanganate 8 mg.l(‐1)
Number of subjects: 50
Study 16704584 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study 16704584 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 15035935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory drug testing program (SATURN) for high school student athletes
Number of subjects: 0
Study 11168516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b (IFN) 5.0 MU, three times a week for 1 year
Number of subjects: 223
Study 11168516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 223
Study 9037645 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (oxygen delivery targeted towards 600 ml/min/m2)
Number of subjects: 0
Study 9037645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9037645 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group
Number of subjects: 0
Study 8198908 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion for induction and maintenance (target concentration 8 micrograms ml-1)
Number of subjects: 163
Study 8198908 — intervention group
Group type: COMPARATOR
Intervention: Propofol bolus (2.5-3.5 mg kg-1)
Number of subjects: 163
Study 8198908 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4-5 mg kg-1)
Number of subjects: 163
Study 8198908 — intervention group
Group type: COMPARATOR
Intervention: Halothane (2-3% for induction, 1-2% for maintenance)
Number of subjects: 163
Study 3280746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine treatment
Number of subjects: 154
Study 3280746 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 154
Study 31301164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min attachment-prime (to enhance attachment-security)
Number of subjects: 68
Study 31301164 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal skills module (control condition)
Number of subjects: 68
Study 30488350 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) 800 mg/m2 bi-weekly and Temsirolimus (T) 10 mg weekly, escalated until dose-limiting toxicities (DLTs) were reached.
Number of subjects: 85
Study 30488350 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) and Temsirolimus (T) combination treatment.
Number of subjects: 85
Study 26104022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapy
Number of subjects: 1050
Study 26104022 — intervention group
Group type: COMPARATOR
Intervention: Triple plus bismuth therapy
Number of subjects: 1050
Study 26104022 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy
Number of subjects: 1050
Study 26258451 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Training Group (ITG) - received RMT using an incentive respiratory spirometer and ADIM using a Stabilizer for 15 minutes a day, five times a week for 6 weeks
Number of subjects: 37
Study 26258451 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Training Group (ITG)
Number of subjects: 37
Study 26258451 — intervention group
Group type: COMPARATOR
Intervention: Respiratory Muscle Training Group (RMTG)
Number of subjects: 37
Study 26258451 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 37
Study 24124451 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAL-HIV-Gag(c) 12 mg
Number of subjects: 23
Study 24124451 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAL-HIV-Gag(c) 24 mg
Number of subjects: 23
Study 24124451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24124451 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAL-HIV-Gag(c)
Number of subjects: 23
Study 21918162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization of ropivacaine 1%, 3 mL before and after surgery
Number of subjects: 60
Study 21918162 — intervention group
Group type: COMPARATOR
Intervention: Instillation of ropivacaine 0.5%, 20 mL after induction of the pneumoperitoneum
Number of subjects: 60
Study 18184832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel coils
Number of subjects: 499
Study 18184832 — intervention group
Group type: COMPARATOR
Intervention: Control (bare platinum coils)
Number of subjects: 499
Study 17996052 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor Training Program (LTP)
Number of subjects: 400
Study 17996052 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise Program (HEP)
Number of subjects: 400
Study 17996052 — intervention group
Group type: EXPERIMENTAL
Intervention: LTP-Early
Number of subjects: 400
Study 17996052 — intervention group
Group type: EXPERIMENTAL
Intervention: LTP-Late
Number of subjects: 400
Study 15269135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromasin (25 mg daily)
Number of subjects: 36
Study 15269135 — intervention group
Group type: EXPERIMENTAL
Intervention: Femara (2.5 mg daily)
Number of subjects: 36
Study 15269135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromasin or Femara
Number of subjects: 36
Study 11359133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL fibrin glue with 4% lidocaine chloride (group C)
Number of subjects: 74
Study 11359133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL fibrin glue using CaCl2 as solution to dissolve thrombin (group B)
Number of subjects: 74
Study 11359133 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 74
Study 9149330 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine (30 mg)
Number of subjects: 7
Study 9149330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8481358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with medroxyprogesterone acetate (MPA) 100 mg t.i.d. p.o. from diagnosis for 90 days
Number of subjects: 218
Study 8481358 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control group)
Number of subjects: 218
Study 2906343 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel (LNG)
Number of subjects: 44
Study 2906343 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinyl estradiol and gestodene (GTD)
Number of subjects: 44
Study 30900508 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical shoulder tests with a brief practical session
Number of subjects: 113
Study 30900508 — intervention group
Group type: COMPARATOR
Intervention: Clinical shoulder tests without a brief practical session
Number of subjects: 113
Study 31743998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi program (3 times a week for 10 months)
Number of subjects: 80
Study 31743998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi program
Number of subjects: 80
Study 31743998 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatments)
Number of subjects: 80
Study 30366588 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH)
Number of subjects: 229
Study 30366588 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Practice (RCP)
Number of subjects: 229
Study 27121007 — intervention group
Group type: COMPARATOR
Intervention: Endometrial injury by endometrial pipelle biopsy (PIP-IVF)
Number of subjects: 1470
Study 27121007 — intervention group
Group type: COMPARATOR
Intervention: Endometrial injury by endometrial pipelle biopsy (PIP-UE)
Number of subjects: 1470
Study 27121007 — intervention group
Group type: COMPARATOR
Intervention: Endometrial injury by endometrial pipelle biopsy (PIP-PCOS)
Number of subjects: 1470
Study 27121007 — intervention group
Group type: COMPARATOR
Intervention: No intervention (PIP-IVF)
Number of subjects: 1470
Study 27121007 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (PIP-UE)
Number of subjects: 1470
Study 27121007 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (PIP-PCOS)
Number of subjects: 1470
Study 24736035 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified London Stroke Carers Training Course (LSCTC)
Number of subjects: 38
Study 22548372 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI
Number of subjects: 21
Study 22548372 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR
Number of subjects: 21
Study 22548372 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR with SBR
Number of subjects: 21
Study 20406217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 20
Study 20406217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 20
Study 20406217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18925531 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine NGAL and IL-18 concentrations measured 2 hours postoperation, corrected for urine creatinine
Number of subjects: 33
Study 18925531 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine NGAL and IL-18 concentrations measured 2-4 hours postoperation
Number of subjects: 33
Study 18925531 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of urine NGAL corrected for urine creatinine and urine IL-18 at 2 hours postoperation
Number of subjects: 33
Study 16238558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring Block (RB) with 1-1.5 ml
Number of subjects: 100
Study 16238558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Block with 1.5-4 ml
Number of subjects: 100
Study 16238558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Ring and Dorsal Penile Block with 2.5-5 ml
Number of subjects: 100
Study 11991432 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive steroid treatment followed by estrogen replacement therapy
Number of subjects: 0
Study 11991432 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 11991432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of estrogens and a progestin
Number of subjects: 0
Study 11991432 — intervention group
Group type: COMPARATOR
Intervention: No estrogen replacement therapy
Number of subjects: 0
Study 10207207 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid surgery
Number of subjects: 108
Study 7596116 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium (100 mg)
Number of subjects: 8
Study 7596116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7596116 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium (100 mg) after salt depletion
Number of subjects: 8
Study 7596116 — intervention group
Group type: COMPARATOR
Intervention: Placebo after salt depletion
Number of subjects: 8
Study 2193713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg flunarizine
Number of subjects: 102
Study 2193713 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg flunarizine
Number of subjects: 102
Study 2193713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 30298964 — intervention group
Group type: EXPERIMENTAL
Intervention: CNL+STEA
Number of subjects: 15
Study 30298964 — intervention group
Group type: EXPERIMENTAL
Intervention: CNL+TEA
Number of subjects: 15
Study 30298964 — intervention group
Group type: COMPARATOR
Intervention: CNL
Number of subjects: 15
Study 30298964 — intervention group
Group type: EXPERIMENTAL
Intervention: CNL+sham-TEA
Number of subjects: 15
Study 28165180 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart (faster aspart)
Number of subjects: 40
Study 28165180 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 40
Study 25758258 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxy maize heat modified starch (WMHMS)
Number of subjects: 10
Study 25758258 — intervention group
Group type: COMPARATOR
Intervention: Uncooked corn-starch (UCCS)
Number of subjects: 10
Study 23140261 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg single dose)
Number of subjects: 62
Study 23140261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metformin)
Number of subjects: 62
Study 21856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (0.5 mg/kg per h)
Number of subjects: 34
Study 21856480 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (various doses from 0.005 to 1.0 mg/kg per h)
Number of subjects: 34
Study 21856480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19247541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitt use during therapy
Number of subjects: 24
Study 19247541 — intervention group
Group type: COMPARATOR
Intervention: No mitt use during therapy
Number of subjects: 24
Study 17215743 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB
Number of subjects: 100
Study 17215743 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/ARG/GLN
Number of subjects: 100
Study 17215743 — intervention group
Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 100
Study 17215743 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB and HMB/ARG/GLN
Number of subjects: 100
Study 15507694 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 30
Study 15507694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15507694 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 11737954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic index-low-fat-high-protein diet
Number of subjects: 12
Study 11737954 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association (AHA) phase I diet
Number of subjects: 12
Study 11737954 — intervention group
Group type: COMPARATOR
Intervention: Pair-fed session (same macronutrient composition as AHA diet)
Number of subjects: 12
Study 9498287 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 182
Study 9498287 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 182
Study 9498287 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking vs Smoking cessation
Number of subjects: 182
Study 8049638 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene, vitamin E, and selenium
Number of subjects: 29584
Study 8049638 — intervention group
Group type: EXPERIMENTAL
Intervention: retinol and zinc
Number of subjects: 29584
Study 8049638 — intervention group
Group type: COMPARATOR
Intervention: riboflavin and niacin
Number of subjects: 29584
Study 8049638 — intervention group
Group type: COMPARATOR
Intervention: vitamin C and molybdenum
Number of subjects: 29584
Study 3189478 — intervention group
Group type: EXPERIMENTAL
Intervention: Biconvex intraocular lens
Number of subjects: 178
Study 3189478 — intervention group
Group type: COMPARATOR
Intervention: Meniscus intraocular lens
Number of subjects: 178
Study 1096536 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 40
Study 1096536 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 40
Study 1096536 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 40
Study 31888723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (95 mg daily for 6 months)
Number of subjects: 130